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Adenosine and inosine are both key intracellular energy substrates for nucleotide synthesis by salvage pathways, especially during
ischemic stress conditions. Additionally they both possess cell protective and cell repair properties. The objective of this study
is to detect potential advantages of the combination of adenosine and inosine versus each drug alone, in terms of ventricular
function, infarct size reduction and angiogenesis. Myocardial ischemia was created in rodents and treated with adenosine, inosine
or their combination. Results of experiments showed that the combination of both drugs signiﬁcantly reduced infarct size
and improved myocardial angiogenesis and ventricular function. The two compounds, while chemically similar, use diﬀerent
intracellularpathways,allowingforcomplementarybiologicalactivitieswithoutoverlapping.Thedrugcombinationatspeciﬁc1:5
adenosine:inosine dose ratio demonstrated positive cardiologic eﬀects, deserving further evaluation as an adjunct to reperfusion
techniques during and after acute coronary syndrome. The association of adenosine and inosine may contribute to reduce
myocardial infarction morbidity and mortality rates.
1.Introduction
Adenosine hasdemonstratedcell-protectiveactivityinanimal
and human models of ischemia reperfusion that involves the
participation of all adenosine receptor subtypes [1, 2]. Ade-
nosine also stimulates the production of vascular endothelial
growth factor (VEGF) which promotes angiogenesis, espe-
cially during and immediately after acute ischemia [3–5].
Inosine is an inotropic agent without chronotropic eﬀect
that does not increase myocardial oxygen consumption [6–
9]. It has also been demonstrated in experimental models
cell-protective activities [10, 11]. Whereas the eﬀects of
adenosine are mediated by the combined function of the en-
tireadenosinereceptorfamily(A1,A2a,A2b,A3),nospeciﬁc
inosine receptor has been identiﬁed to date at the level of
vascularandcardiaccells.Therefore,pathwayssupportingits
eﬀects remain uncertain and most of them are presumed to
be energy restoration mechanisms [11].
A combination (mixture) of the two nucleosides adeno-
sine and inosine at a speciﬁc 1:5 dose ratio has been found
to synergistically enhance arterial vasodilation and be hae-
modynamically equivalent to adenosine optimal dose alone,
using a dose of adenosine cut by 50%.
Given, ﬁrstly, that ATP and energy nucleoside substrates
depletion is a rapid process and the major cause of death
in myocardial cells submitted to acute ischemic conditions,
and, secondly, that adenosine and inosine both possess cell
protective and repair activities, we found interesting to assess
in an acute coronary syndrome model with reperfusion
injury, the potential therapeutic value of their combination
at optimal hemodynamic adenosine:inosine dose: ratio of
1:5.
The objective of the present study is to detect the exis-
tence, in a widely used acute ischemia experimental model,
of potential advantages of the combination of adenosine and2 ISRN Cardiology
inosine versus each drug alone, in terms of ventricular func-
tion, infarct size reduction, and angiogenesis.
2.MaterialsandMethods
After creation of a left ventricular (LV) acute myocardial in-
farction in rats followed by reperfusion, adenosine and ino-
sine drugs used alone or in combination were intravenously
infused for one hour. Evaluation included LV function
assessment by echocardiography and histological studies of
myocardial tissue.
2.1. Products. Both adenosine (Adenosine A9251) and ino-
sine (Inosine I4125) were obtained from Sigma-Aldrich
Chemical, Evry, France.
2.2. Doses Finding and Search for an Optimal Adeno-
sine:Inosine Dose Ratio. Search for a correlation between
doses in the rat and those employed in the human was a
prerequisite for this experiment.
In a ﬁrst series of 5 animals (all excluded from the ACS
p r o t o c o l ) ,c a r o t i db l o o dﬂ o wm e a s u r e m e n t sw e r eu s e dt o
determine which dose in the rat induces maximal carotid
blood ﬂow and correlates to the dose described in the man,
that is, 120–140μg/kg/mn [12, 13]; from there the dosage
that in the rat approximately corresponds to adenosine
50–70μg/kg/mn, as had been IV given to patients with
A C Si ns e v e r a lh u m a nt r i a l s[ 14–16], was easy to estimate.
We used starting doses drawn from the data published
by Ohnishi et al. [17] about the eﬀect of adenosine on
blood pressure measured at the carotid artery level in the
normotensive rat, because no reference speciﬁcally focused
on CaBF after adenosine administration could be found
in the literature with this animal. Finally the ﬁxed dose
of adenosine 0.05mg/kg/mn was identiﬁed in the rat as
equivalent to 50–70μg/kg/mn in the human.
In further series of rats (5 per group, six groups)
incremental doses of inosine were combined with this ﬁxed
dose of adenosine (equivalent to 50% adenosine max) and
administered intravenously; the eﬀect of these combinations
on CaBF was then compared to that of adenosine max.
This methodology allowed us to select 1:5 as the optimal
adenosine:inosine dose: ratio combination providing maxi-
mal CaBF.
2.3. Myocardial Ischemia/Reperfusion Injury. In Wistar rats
(weight 300 ± 30g) a left ventricular myocardial ischemia
was surgically created by transitory left coronary artery
surgical occlusion (45 minutes), followed by reperfusion.
All procedures were approved by the French National
Institute of Health and Medical Research and received care
in compliance with the European Conventions.
2.4. Anesthesia. Rats were anesthetized with a mixture of
ketamine (Panpharma, Fougeres, France) 50mg/kg and ace-
promazine (Vetranquil, Sanoﬁ-Aventis, Libourne, France)
2mg/kg, using intramuscular injections. An endotracheal
metallic tube was inserted through the mouth for artiﬁcial
respiration using air, maintained with a Harvard Rodent
Ventilator model 683 (frequency 85cycles/min, tidal volume
20mL).
2.5. Surgical Procedures. In the supine position, a left antero-
lateral thoracotomy was performed via the fourth intercostal
space. The pericardium was opened and the left coronary
artery and its branches were localized using magnifying
glasses. A 6-0 nonabsorbable Prolene suture was passed
underneath the left coronary artery (just proximal to their
division), the ﬂow was interrupted using a 5F polyurethane
occluder. This occluder was released after 45 minutes,
therefore the myocardial ischemic territory was reperfused.
Signiﬁcant EKG changes, including widening of the QRS
complex and elevation of the ST segment, and color changes
of the area at risk were considered indicative of coronary
occlusion. The intercostal space was then closed with a 6-
0 nonabsorbable Prolene suture and the skin with a 5-0
absorbable Vicryl suture. One hour after closure baseline
echocardiography was performed. The animals with a base-
line LV ejection fraction higher than 30% were eliminated
from the study. Afterwards the femoral vein was surgically
e x p o s e d ,a2 4G ,1 8m mP T F Ec a t h e t e r( I n t r a f o n2V y g o n ,
Ecouen, France) was inserted for infusion of a therapeutic
solution during 60 minutes using an electrical infusion
pump.
2.6. Treatment Groups. After creation of myocardial ische-
mia, animals were randomized for IV infusion of:
Group 1 (n = 12): saline (sham group);
Group 2 (n = 12): adenosine at the dose of 0.05mg/
kg/min;
Group 3 (n = 12): inosine at the dose of 0.25mg/kg/min;
Group 4 (n = 12): combination of adenosine at the dose
of0.05mg/kg/mnwithinosineatthedoseof0.25mg/kg/min
(1:5).
2.7. Functional Evaluation. Echocardiography studies were
performed using a Sequoia Acuson system 512 (with a
15MHz probe), one hour after myocardial ischemia (base-
line) and at postoperative day 45. Echocardiography assessed
LV ejection fraction (EF), end-systolic, and end-diastolic
ventricular diameters and volumes.
2.8. Histological Studies. After echocardiography rats were
killed at postoperative day 45. The hearts were ﬁxed in 4%
formaldehyde solution for 48h, and then dissected. For each
case numerized photographic was obtained before and after
dissection. After ﬁxation the hearts were cut transversally in
the middle third between base and apex in sections of 2mm
and paraﬃn embedded. For histological analysis 5μ tissue
section performed and a usual HES staining was performed.
2.8.1. Immunohistochemistry. It was performed using mar-
keted monoclonal antibody antifactor VIII (1/400, Dako).
Brieﬂy, tissue sections were antigen-retrieved in 0.1M
citrate buﬀe r ,p H6 ,i nah o ts t e a m e rf o r3 0 m i n .T h e
immunostaining process was performed on a Dako StainerISRN Cardiology 3
Table 1: Echocardiographic LV functional evaluation.
Group Individuals LV ejection
fraction SD
Adenosine + Inosine n = 12 0.644 0.087
Adenosine n = 12 0.631 0.086
Inosine n = 12 0.610 0.063
Sham n = 12 0.491 0.123
Ejection fraction at 45 days showed a signiﬁcant diﬀerence between the
four groups (Welch’s ANOVA P = 0.015). C Dunnett test for pairwise
comparison was signiﬁcant for combination versus sham (superiority
at 0.05, mean of the diﬀerence = 15.2%) and adenosine versus sham
(superiority at 0.05, mean of the diﬀerence = 14%).
processor at ambient temperature. Subsequently, slides were
incubated with the antifactor VIII antibody, biotinylated
secondary anti-mouse/anti-rabbit mixed antibody with the
same avidine-peroxidase complex (Dako), and chromogenic
substrate diaminobenzidine; slides were then counterstained
with hematoxylin. Capillary density was evaluated on HES
slides after Factor VIII immunohistostaining.
2.9. Infarct Size Evaluation. For each case a percentage
infarction of the LV surface was evaluated by a millimetric
scale section (square surface of infarction). For each section
the surface of infarction was calculated using a micrometer
(Lmax × lmax). The infarct volume was evaluated by the
number of infarcted section observed.
2.10. Angiogenesis Index. An angiogenesis index was deﬁned
and calculated. A semiquantitative method was used to score
angiogenesis in the infarct area. To reduce inter-animal
variations we arbitrarily deemed more relevant to use a scale
considering a 5 capillaries diﬀerence/animal rather than the
total number of capillaries per group:
no arterial capillary = 0;
less than 5 capillaries = 1;
between 5 and 10 = 2;
between 10 and 15 = 3;
over 15 = 4.
The angiogenesis index was calculated as the mean of the
total angiogenesis score per group. As for an example the
total angiogenesis score for the inosine-alone group was
calculated as the sum of all angiogenesis scores (one per rat)
divided by the number of animals (n = 1 2 ) :1+3+2+4+
2+2+3+3+3+2+3+4= 32/12 = 2.6.
2.11. Statistical Analysis. An exploratory analysis was ﬁrst
conducted to study the distribution of the variables using
the Kolmogorov-Smirnov test and graphical methods.
Homoscedasticity was also studied via the Levene test. In
case of heteroscedasticity the Welch’s ANOVA was used
rather than the one-way ANOVA analysis of variance (in
this situation ANOVA may yield inaccurate P values). When
variablesshowedabnormaldistributiontheH testofKruskal
Wallis(nonparametricequivalentofANOVA)wasemployed.
To further conduct pairwise comparisons (in case of
signiﬁcant P values with Welch’s Anova or Kruskal Wallis
test), we used the C Dunnet test (if heteroscedascity) or
the nonparametric version of the Student-Newman-Keuls
(SNK) for multiple comparisons. The C Dunnet test and
SNK were preferred to other methods to avoid overesti-
mate of the P-value when performing multiple comparison
studies. A 0.05 level was considered signiﬁcant for all the
tests. Statistical procedures were performed using IBM SPSS
Statistics 18.
3. Results
3.1. Mortality Rate. The operative mortality rate of our is-
chemia-reperfusion model was 11%. The mortality rate dur-
ing the follow-up period was 3%. Animals included into the
study to replace dead animals were randomly assigned to one
grouportheotheruntiltheﬁnalnumberofsurvivorsreaches
12 in each group.
After the double-blind code was broken the mortality
rate during the whole study (perioperative + follow-up
periods) appeared slightly higher in the sham (7%) and
adenosine (8%) groups as compared to the inosine (3%) and
drug combination (3%) groups.
3.2. Functional Evaluation. Echocardiography studies
showed that LVEF was similarly preserved 45 days after
myocardial infarction in the treated rat groups by either
adenosine, inosine or their combination, as compared
to the sham group. However, a signiﬁcant diﬀerence was
demonstrated in the drug combination and adenosine alone
groups versus sham, but not between inosine and the sham
group (Table 1).
3.3. Histological Diagnosis. In the adenosine group the mean
infarct size was 2.60mm3 and the angiogenesis median index
was 2. In the inosine group the mean infarct size was
2.62mm3 and the angiogenesis median index was 3. In the
adenosine/inosine combination group the mean infarct size
was 1.70mm3 and the angiogenesis median index was 4.
For the control group the mean infarct size was 3.79mm3
and the angiogenesis median index was 1.5. A signiﬁcant
diﬀerence was observed regarding infarct size between the
drugcombinationandadenosinegroupsandtheshamgroup
(Table 2).
On histologic analysis we found that inosine, adenosine,
and drug combination groups had a proangiogenic eﬀect
superiortotheshamandinparticularthatadenosine/inosine
combination, besides being signiﬁcantly better than the
control, was also signiﬁcantly superior to adenosine in this
regard. (Figures 1(a) and 1(b)).
4. Discussion
Adenosine is a strong coronary vasodilator, and for this rea-
son is used worldwide as a pharmacological stressor for the
imaging of myocardial perfusion and the detection of coro-
nary artery disease [18, 19]. Adenosine’s ability to suppress4 ISRN Cardiology
Table 2: Infarct size and angiogenesis.
Group Mean infarct size
(mm3)
Angiogenesis median
index
Adenosine + inosine 1.70 ± 0.18 4
Adenosine 2.60 ± 0.2 2
Inosine 2.62 ± 0.3 3
Sham 3.79 ± 0.45 1.5
The Kruskal Wallis test for the diﬀerence between the four groups was
signiﬁcant at the 0.05 level (P = 0.02 for the infarct size endpoint and
P<0.01 for the angiogenesis index). Using the nonparametric post hoc test
(Student Newman Keuls for balanced samples) at the 0.05 level infarct size
for both the combination and adenosine groups as compared to the sham
group was signiﬁcantly smaller. The combination drug approach showed a
signiﬁcantandbetterproangiogeniceﬀectversusadenosineandversussham
groups. At the 0.05 level all treated groups (adenosine, combination, and
inosine) were superior to the control group.
the biological pacemaker activity and to slow atrio-
ventricularconductionisalsousedinclinicalpractice,forthe
treatment of supraventricular tachycardia [20]. In addition,
adenosine also possesses well-documented cell-protective
and cell-repair activities [1–5]. However, its protective and
restorative eﬀects have been more convincingly demon-
strated in animal studies than in human clinical studies.
Furthermore, adenosine has a poor tolerability; this remains
a serious limiting factor that, until now, greatly contributed
to restrict the scope of its medical applications, especially
when prolonged infusion times are indicated (i.e., 0.5 to 3
hours) in conscious patients. Therefore, although referenced
as a major cell-protective agent, adenosine has not yet been
cleared for such purpose by the regulatory authorities and
therefore remains under investigation.
Inosine, the primary byproduct of adenosine, has been
longconsideredarelativelyeitherinactiveorweakmetabolite
(e.g., it is a weak coronary vasodilator, ten times less potent
than adenosine) and has been somewhat “brushed aside,”
not to say forgotten by the scientiﬁc cardiologist community
during the last decades. Yet, it should be remember that
inosine has been used as an inotropic agent for more
than 20 years in several countries (France, Germany, Japan,
Russia) due to its capacity for increasing cardiac output
without chronotropic eﬀect and increase of myocardial
oxygenconsumption[21–24].However,withtheappearance
of new and more competitive inotropic drugs, it was no
longer commercially sold after the early 1980s.
Interestingly, and as opposed to adenosine, inosine is
extremely well tolerated in humans, so much so that in
the countries that marketed it, it was the preferred drug
for patients over 65 years old with heart failure [2]. Recent
evidence indicates that extracellular inosine has potent
abilities to protect and repair cells, due to anti-inﬂammatory
properties, as well as the ability to stimulate various growth
factors and restore cell energy [11, 25–28].
In addition, due to a competitive mechanism between
the two molecules at the level of speciﬁc cell membrane
transporters (“equilibrative nucleoside transporters 1 and
2”) [29], the concurrent administration of adenosine and
inosine makes it possible for inosine to interfere with ade-
nosine in real time, to modulate its plasma clearance in a
dose-dependentfashionwithoutlosingadenosineimmediate
reactivity (side eﬀects cease rapidly after cessation of the
infusion) and thus to reduce adenosine doses without loss of
eﬃcacyandimprovedsafety.Theﬁnaleﬀectmaybeachieved
for long infusion times (0.5 to several hours) and cannot be
performed as safely and accurately (in a steady-immediate
fashion, second after second) by other existing molecules,
thanks to adenosine and inosine short half-lives.
In the present study which was strictly focused on cell
protection and angiogenesis end-points, we observed that
theadenosine/inosinecombinationeﬀectssurpassedthoseof
adenosine and inosine alone.
4.1. Adenosine and Inosine Pathways. It is known that under
hypoxic condition and contrary to normoxic conditions,
myocardial cells produce great quantities of both adenosine
and inosine (Figures 2 and 3). Said brieﬂy during hypoxia
adenosine is utilized mainly for cell protection mechanisms,
via stimulation of myocardial cell and endothelial cell
adenosine A1, A2, and A3 receptors leading to various
biological eﬀects including activation of the mitochondrial
K+ ATP dependent channels [30–33] while inosine is
used for cell energy repletion [8, 11], these two eﬀects
being complementary (Figure 3). Well documented is also
adenosine’s ability to inhibit neutrophil cells migration, to
reducefreeradicalproduction[34,35],todownregulatepro-
inﬂammatory cytokines (such as TNF-α,I L - 6 ,I F N - γ,I L -
12). Also well known is inosine’s ability to attenuate many
pro-inﬂammatory cytokines such as IL-1 and macrophage-
inﬂammatory protein-1 α [25, 26]. Importantly, it was
observed that the increase in adenosine and inosine for-
mation during myocardial ischemic events is not always
suﬃcient to supply needs. After only a few hours, persistent
ATP depletion followed by adenosine and inosine depletion
can lead to cell death. This has justiﬁed the use, in several
human clinical trials (e.g., Attac and Amistad studies,
ref. [14–16]), of exogenous adenosine as an adjunct to
reperfusion techniques performed within the ﬁrst 6 hours
in patients with acute coronary syndrome. These studies
showed interesting outcomes like a signiﬁcant reduction of
infarct size, but unfortunately no clear reduction of patients’
mortality and morbidity rates. In addition no signiﬁcant
improvement of cardiac function was demonstrated. Thus,
there was some general disappointment at the results, along
withtheoverallfeelingthatadenosinetherapeuticeﬀectsand
its related methods of use during or after acute myocardial
infarction events could be greatly optimized. To achieve this
goal diﬀerent approaches are possible such as the use of
speciﬁc adenosine agonists or adenosine regulating agents
with some of them having shown in ACS animal models
interesting preclinical results [36, 37]. Here we tested what
can be labeled the “nucleoside approach,” not only because
of the various biological activities described above but also
because adenosine and inosine are critical energy substrates
during acute ischemia (Figures 2 and 3). In this regard it
shouldbenoted thatadenosine wasrecentlyshownto stimu-
late the AMP-activated protein kinase (AMPK) pathway [38]ISRN Cardiology 5
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Figure 1: Histological analysis: focus of signiﬁcant infarct scar (surrounded by black lines). Comparative angiogenesis in the infarct area,
capillary density is on average higher in the combination group compared to other groups, 1: sham, 2: combination, 3: inosine, 4: adenosine.
(a) Staining technique HES (magniﬁcation: Obj. ×20). (b) Immunohistochemistry using antifactor VIII (magniﬁcation: Obj. ×40). Arrows
show capillaries neovascularisation.6 ISRN Cardiology
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Figure 2: Adenosine and inosine pathways in normal conditions. During “normoxia” adenosine is released in small amounts at a constant
basal rate partly from hydrolysis of S-adenosyl homocystein (SAH) by SA-homocysteinase and mostly by dephosphorylation of AMP
by 5 ecto-nucleotidases (5 EN) localized in the cytosol or membrane-bound outside the cells. From there, intracellular adenosine is
rephosphorylated to AMP by adenosine kinase and a small amount is released from the cell. Indeed the values of the Km of adenosine
kinase for adenosine are between one and two orders of magnitude lower than those for the deaminase which is much less active.
Therefore, it is thought that 5 -nucleotidase and adenosine kinase are simultaneously active so that a substrate cycle between AMP and
adenosine is produced. Inosine production depends on adenosine basal production. It is formed by the deamination of adenosine and
is metabolized to ribose-1-phosphate and hypoxanthine by purine nucleoside phosphorylase and further to xanthine and uric acid by
xanthine deshydrogenase. Consequently, plasma levels of free adenosine in normoxic conditions are extremely low (0.1-0.2μmol/L) and
those of inosine almost undetectable (0.01–0.1μmol/L).
known to play an important role in restoring the energy
balance. AMPK activation increases glucose uptake (leading
to pyruvate synthesis and ATP production) and free fatty
acids metabolism. Interestingly decrease of free fatty acids
uptake and increase of carbohydrates uptake can also be
induced by infusion of inosine alone as has been described
previously [8]. However, the existence of a link between
inosine and the AMPK pathway has not yet been studied.
4.2. Optimization of Adenosine Method of Use. Regarding
the method of treatment, several studies assessed the eﬀect
of adenosine given through the coronary arteries during
percutaneous cardiologic interventions. Positive results were
obtained when adenosine was given by infusion of 20
minutes or more [39] and negative results were obtained
when it was given as a bolus [40]. Consistent with adenosine
extremely short half life (a few seconds) it is thus conﬁrmed
that bolus administration, as opposed to long infusion times
is not eﬀective whatever the intravascular route selected,
intra-arterial or intravenous. Moreover, if long infusion
times are required to ensure adenosine eﬃcacy it is likely
that non invasive routes of administration (intravenous) will
appear more adequate in the future compared to intracor-
onary or intracardiac routes.
Improvement of the method of administration regarding
the timing of reperfusion is also critical for cardioprotection.
Given the impact of time [41] future studies in the human
will have to restrict the administration of drug combination
adenosine/inosine employed as a potential protective agent
to those patients who can be treated within the ﬁrst 3–3.5
hours after onset of symptoms.
With regard to the myocardial healing process, the use
of subsequent drug combination infusions following the
ﬁrst infusion might also be assessed. Repetition of infusions
during the days after myocardial infarction so as to further
stimulate angiogenesis could lead to additional beneﬁcial
eﬀect. Another justiﬁcation of repeated administration is the
fact that adenosine reduces the release of noradrenaline, the
production of endothelin and attenuates activation of the
renin-angiotensin system, all of which are thought to cause
cardiac hypertrophy and remodeling [42].
4.3. Optimization of Adenosine Eﬀects. Regarding the en-
hancement of adenosine’s protecting and repairing activities,ISRN Cardiology 7
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Figure 3:Adenosineandinosinepathwaysinhypoxicconditions(stress).During“cellularstress”conditions(e.g.,hypoxia)theproductionof
adenosineincreases.Ectoandendo5 NTenzymesmainlycontributetotheproductionofadenosineincells.TherateofSAHhydrolysisdoes
not increase much (1.5-fold). When adenosine levels increase, adenosine deamination predominates and inosine reaches high concentration
inside the cell. It is then shunted into the extracellular space by bidirectional equilibrative nucleoside transporters and interstitial levels of
inosine can rise to greater than 1mM. An array of evidence now suggests that under hypoxic conditions the phosphorylated ribose moiety
of inosine is used for energy repletion through anaerobic glycolysis as an alternative or complementary to glucose. Inosine can generate ATP
through the hypoxanthine-IMP-AMP pathway or through the anaerobic pentose pathway (Ribose1P). Hypoxanthine is rephosphorylated to
inosine monophosphate using phosphoribosyl pyrophosphate (PRPP), leading to IMP and further AMP. At pH 7.4 ribose-1-phosphates can
be converted to ribose-5-phosphate which rebuilds the purine ring system and can restore ATP via the anaerobic pentose pathway.
we hypothesized that the administration of exogenous ino-
sine, in addition to adenosine, at speciﬁc adenosine:inosine
dose ratios, might optimize the “nucleoside eﬀect” and
improve adenosine’s performance. We tested this hypothesis
using an animal model that reproduced the same adenosine
protocol design as applied in the human for acute coronary
syndrome, the same sequence of naturally occurring events,
namely, acute ischemia followed by myocardial reperfusion,
while the doses of infused nucleosides were correlated to
those employed in patients. The presented results showed
that the drug combination used at a speciﬁc adeno-
sine:inosine 1:5 ratio was at least equivalent to adenosine
and inosine alone to improve cardiac function (Table 1)a n d
superior to both of them to reduce infarct size (Table 2).
In addition whereas the ability of adenosine to stimulate
angiogenesis is well documented we also found that inosine
had a myocardial proangiogenic activity of its own at least as
potent as that of adenosine (Table 2). This angiogenic eﬀect
seemstobeampliﬁedwhenthetwonuclosidesarecombined.
It has been suggested that inosine could selectively induce
angiogenesis in porcine aortic endothelial cells cultivated
in vitro [43] via ﬁbroblast growth factor (FGF) known as
a strong angiogenesis promoter [44]. Thus, although still
hypothetical, there is some ground to conduct additional
studies for checking if the proangiogenic activity of the
adenosine/inosine combination may involve the concurrent
stimulation of both VEGF and FGF mediated by adenosine
and inosine respectively.
Additionally, it has been suggested that AMPK pathway
stimulation by adenosine, besides its important energetic
role during acute ischemic conditions, could also actively
participate to various steps of the proangiogenic cascade,
such as for example endothelial cells migration [38].
In summary, our results indicate that adenosine and
inosine are likely to have cell protective and repairing eﬀects
that can be enhanced when they are administered simulta-
neously. It should be highlighted that the two compounds,
while chemically similar, use diﬀerent intracellular pathways,
allowing for complementary biological activities without
overlapping. This makes their combined use logical and
promising for the targeted indication. Further studies are
neededtoconﬁrmthatthedrugcombinationisanoptimized
therapeutic form of adenosine and thus might be proposed
as an adjunct to reperfusion procedures in acute coronary8 ISRN Cardiology
syndrome patients as well as an agent with the ability to
accelerate the healing process after myocardial infarction.
Final hope is that the addition of all the optimization factors
described here may contribute to further reduce myocardial
infarction morbidity and mortality rates.
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